Showing 12,241 - 12,260 results of 12,700 for search '"cancers"', query time: 0.09s Refine Results
  1. 12241

    Volatile Organic Compounds and Carbonyls Pollution in Mexico City and an Urban Industrialized Area of Central Mexico by Elizabeth Vega, Omar Ramírez, Gabriela Sánchez-Reyna, Judith C. Chow, John G. Watson, Diego López-Veneroni, Monica Jaimes-Palomera

    Published 2022-04-01
    “…A health risk assessment for toxic species such as benzene, toluene, ethyl benzene and xylenes (BTEX), found a decreasing trend from 2006 to 2012. Lifetime cancer risks (LCR) from benzene ranged from 1.5 × 10−5 to 6.1 × 10−5 in 2006 and from 8.8 × 10−6 to 2.2 × 10−5 in 2012 for the urban MER site. …”
    Get full text
    Article
  2. 12242

    siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: an in silico and in vitro study by Muhammad Hossein Ashoub, Ali Afgar, Alireza Farsinejad, Razieh Razavi, Samira Anvari, Ahmad Fatemi

    Published 2025-01-01
    “…Given that hTERT overexpression characterizes various cancer phenotypes and elevated telomerase activity is observed in early-stage and relapsed ALL, we investigated the molecular mechanisms linking hTERT regulation and ferroptosis in leukemia cells. …”
    Get full text
    Article
  3. 12243
  4. 12244

    Phytochemical, Cytotoxic, and Antimicrobial Evaluation of the Fruits of Miswak Plant, Salvadora persica L. by Mohammed Al Bratty, Hafiz A. Makeen, Hassan A. Alhazmi, Sohier M. Syame, Ashraf N. Abdalla, Husham E. Homeida, Shahnaz Sultana, Waquar Ahsan, Asaad Khalid

    Published 2020-01-01
    “…The fruit extract of S. persica was selective against the ovarian and colon cancer cells compared to normal fibroblast cells (MRC5) as it showed IC50 values 17.50, 8.35, and 5.12, against MCF7, A2780, and HT29 cells, respectively. …”
    Get full text
    Article
  5. 12245
  6. 12246

    Genetic polymorphism of CYP1A1 and CYP2D6 in populations of Buryats, Teleuts and Russians of Eastern Siberia by L. E. Tabikhanova, L. P. Osipova, T. V. Churkina, E. N. Voronina, M. L. Filipenko

    Published 2018-04-01
    “…The obtained data makes it possible to predict a reduced risk of side effects of drugs and cancer associated with CYP2D6*3 (2549del) and CYP2D6*4 (1846A) in the Buryat and Teleut populations. …”
    Get full text
    Article
  7. 12247

    Cultural adaptation of ENABLE (Educate, Nurture, Advise, Before Life Ends) an early palliative care model for Iranian patients with heart failure and their caregivers: a qualitativ... by Arvin Mirshahi, Ali Khanipour-Kencha, Marie Bakitas, J. Nicholas Odom, Rachel Wells, Arpi Manookian

    Published 2025-01-01
    “…Abstract Background ENABLE (Educate, Nurture, Advise, Before Life Ends) is a model of nurse-led, early palliative care that was originally developed for U.S. patients with advanced cancer and their family caregivers and then adapted for patients with heart failure. …”
    Get full text
    Article
  8. 12248

    Consumo alimentar de pacientes oncológicos: onde estão as inadequações? by Simone dos Anjos Caivano, Amanda Cristina Torralbo Pugliesi, Semíramis Martins Álvares Domene, Fabiola Pansani Maniglia

    Published 2024-12-01
    “…Introdução: Os hábitos alimentares podem influenciar diretamente no estado de saúde do indivíduo, e modulam o risco para doenças crônicas não transmissíveis, como o câncer. Objetivo: Avaliar a qualidade da dieta de indivíduos em tratamento oncológico. …”
    Get full text
    Article
  9. 12249

    Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience by Loredana De Pasquale, Antonio Mario Bulfamante, Giovanni Felisati, Luca Castellani, Giorgio Ghilardi, Alberto Maria Saibene

    Published 2021-01-01
    “…Parathyroid carcinoma (PC) is the rarest endocrine cancer and an infrequent cause of primary hyperparathyroidism (PHPT), responsible for less than 1% of cases. …”
    Get full text
    Article
  10. 12250
  11. 12251

    Risk Factors for Hospital Readmission Following Noncardiac Surgery: International Cohort Study by Michael H. McGillion, RN, PhD, Flavia K. Borges, MD, PhD, David Conen, MD, MPH, Daniel I. Sessler, MD, Brenda L. Coleman, RN, PhD, Maura Marcucci, MD, MSc, Carley Ouellette, RN, MSc, Marissa Bird, RN, PhD, Carly Whitmore, RN, PhD, Shaunattonie Henry, RN, PhD, Sandra Ofori, MD, MSc, Shirley M. Pettit, RN, Deborah M. Bedini, RN, MHS, Leslie P. Gauthier, MScT, Jennifer Lounsbury, RN(EC), MN, Nancy M. Carter, RN, PhD, Vikas Tandon, MD, Ameen Patel, MD, Teresa Cafaro, MD, MSc, Marko R. Simunovic, MD, John A. Harlock, MD, Diane Heels-Ansdell, MSc, Fadi Elias, MD, MS, Theodore Rapanos, MD, Shawn Forbes, MD, Elizabeth Peter, RN, PhD, Judy Watt-Watson, RN, PhD, Kelly Metcalfe, RN, PhD, Sandra L. Carroll, RN, PhD, Philip J. Devereaux, MD, PhD

    Published 2024-06-01
    “…Multivariable analyses demonstrated that 9 baseline characteristics (eg, cancer treatment in past 6 months; adjusted hazard ratio [HR], 1.44; 95% CI, 1.30–1.59), 5 baseline laboratory and physical measures (eg, estimated glomerular filtration rate or on dialysis; HR, 1.47; 95% CI, 1.24–1.75), 7 surgery types (eg, general surgery; HR, 1.86; 95% CI, 1.61–2.16), 5 index hospitalization events (eg, stroke; HR, 2.21; 95% CI, 1.24–3.94), and 3 other factors (eg, discharge to nursing home; HR, 1.61; 95% CI, 1.33–1.95) were associated with readmission. …”
    Get full text
    Article
  12. 12252

    Impact of hospital formulary intervention on carbapenem use: a segmented time-series analysis of consumption and a propensity score-matched non-inferiority study of treatment effic... by Nakaba Okamura, Ayano Katagiri, Tomoya Komori, Kei Kawanabe, Hirofumi Koike, Yukiko Sahashi, Rie Kubota

    Published 2025-01-01
    “…To assess treatment efficacy, we used non-inferiority analysis with propensity score matching based on age, sex, body mass index, cancer status, and baseline blood test results. The treatment outcomes were evaluated using predefined clinical indicators. …”
    Get full text
    Article
  13. 12253

    MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience by C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, Sheldon Feldman

    Published 2012-01-01
    “…The MammaPrint (MP) diagnostic assay stratifies breast cancer patients into high- and low-risk groups using mRNA analysis of a 70-gene profile. …”
    Get full text
    Article
  14. 12254

    Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database by Hanzhang Yuan, Jingsheng Cheng, Jun Xia, Zeng Yang, Lixin Xu

    Published 2025-01-01
    “…Patients and methods Differentially expressed genes (DEGs) of glioma were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. …”
    Get full text
    Article
  15. 12255

    Protocol for a randomised ‘screen-and-treat’ Helicobacter pylori eradication trial in 14–18-years-old adolescents residing in three regions of Chile: effectiveness and microbiologi... by Ximena Aguilera, Camila Cabrera, Sergio George, Yalda Lucero, Beatriz Zabala Torres, Lilian Fernández, Nora Mamani, Anne Lagomarcino, Miguel O'Ryan

    Published 2025-01-01
    “…Introduction Gastric cancer is a major global health concern, being the final stage of a long-term process, primarily associated with Helicobacter pylori (H. pylori) infection. …”
    Get full text
    Article
  16. 12256

    Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1 by Cunru Zou, Yu Zhang, Chengyue Liu, Yaxin Li, Congjie Lin, Hao Chen, Jiangping Hou, Guojun Gao, Zheng Liu, Qiupeng Yan, Wenxia Su

    Published 2025-01-01
    “…Data from RNA‐seq and microarray were analyzed to reveal correlations of the CENPM gene with cancer, metastasis, and survival in ACC. Immunohistochemistry was used to assess CENPM protein expression. …”
    Get full text
    Article
  17. 12257

    Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors by Guihong Yang, Yimei Wang, Huimin Zhao, Ziyi Jiang, Shansong Zheng, Mingjing Ge, Meimei Si, Xiaoyan Kang

    Published 2025-01-01
    “…Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib therapy. …”
    Get full text
    Article
  18. 12258

    Impacts of Sandstorms on Chemistries of Ambient PAHs in a Small City in North China by Zhiyong Li, Zhen Zhai, Jixiang Liu, Lan Chen, Zhuangzhuang Ren, Chen Liu, Ziyi Zhan, Ziyuan Yue, Wenjia Zhu, Jihong Wei, Huiying Gao, Songtao Guo

    Published 2023-03-01
    “…Accordingly, the largest contributor of incremental lifetime cancer risks (ILCRs) changed from vehicle exhaust (VE) (36.2%) in the NSSP to OLC (34.4%) in the SSP. …”
    Get full text
    Article
  19. 12259

    Comparative Evaluation of Functional Outcomes in High Condylar Fractures Treated with Closed Methods with and without Temporomandibular Joint Arthrocentesis: A Research Protocol fo... by Sachindra Dubey, Nitin Bhola, Anchal Agarwal

    Published 2025-02-01
    “…Materials and Methods: A randomised controlled trial will be conducted at Siddharth Gupta Memorial Cancer Hospital, Sawangi, Wardha, Maharashtra, India, from September 2024 to May 2026, involving 10 patients. …”
    Get full text
    Article
  20. 12260

    Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach by Jonathan Dounel, Carolyn Lamorte, Heather Patton, Ponni Perumalswami, Heather McCurdy, Nicole J. Kim, Lauren A. Beste, Dawn Scott, Jessimarie Casey, Patrick Spoutz, Linda Chia, Yiwen Yao, Elliott Lowy, Sandra Gibson, Timothy R. Morgan, Shari S. Rogal

    Published 2025-01-01
    “…Of 488 patients whose charts were reviewed, 230 were excluded from outreach based on predefined criteria (e.g., advanced cancer, prior or current referral to hepatology). …”
    Get full text
    Article